Renal cancer
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma. A Single Technology Appraisal. 2020.
Blood and bone marrow cancer
Mistry H, Nduka C, Connock M, et al Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 2017
Venetoclax for treating chronic lymphocytic leukaemia. A Single Technology Appraisal. 2017
Loveman E, Cooper K, Bryant J, Colquitt J, Frampton G, Clegg A. Dasatinib, high dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technology Assessment. 2012;16 (23).
Breast cancer
Abemaciclib with an aromatase inhibitor for untreated advanced hormone receptor-positive, HER2-negative breast cancer. A Single Technology Appraisal. 2019
Takeda A, Jones J, Loveman E, Tan SC, Clegg AJ. The clinical and cost effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation. Health Technology Assessment 2007;11(19).
Picot J, Copley V, Colquitt JL, Kalita N, Hartwell D, Bryant J. The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation. Health Technology Assessment 2015; 19(69).
Liver cancer
Loveman E, Jones J, Clegg A, Picot J, Colquitt J, Mendes D, et al. The clinical effectiveness and cost effectiveness of ablative therapies in the management of liver metastases: systematic review and economic modelling study. Health Technology Assessment 2014;18(7).
Lung cancer
Dacomitinib for untreated EGFR-positive non-small-cell lung cancer. A Single Technology Appraisal. 2019
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer. A Single Technology Appraisal. 2016
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer. A Single Technology Appraisal. 2016
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer. A Single Technology Appraisal. 2016
Hartwell D, Jones J, Loveman E, Harris P, Clegg A, and Bird A. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer Treatment Reviews 2011;37:242-249.
Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K et al. The clinical and cost effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technology Assessment 2010;4(19)
Colquitt J, Jordan M, Court R, Loveman E, Parr J, Ghosh I et al Artificial intelligence software for analysing chest X-ray images to identify suspected lung cancer: an evidence synthesis early value assessment Health Technology Assessment 2024; 28 (50)
Skin cancer
Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma. A Single Technology Appraisal. 2019
